[Exposed] The “Quack” Treatment That’s Killing Cancer

For decades, you’ve been sold a simple idea: If it sounds too easy, it can’t work.

Especially when it comes to cancer.

Because in modern medicine, the “serious” treatments are always the harsh ones:
Chemotherapy. Radiation. Toxic drugs with long lists of side effects.

So when one of the greatest scientific minds in history made a shocking claim late in his life…

He was ridiculed.

Mainstream medicine dismissed him.

Critics attacked his credibility.

Entire watchdog groups still cite his work as an example of “quackery” to this day.

But now, the very idea they buried is quietly making a comeback inside research labs, cancer clinics, and even mainstream medical publications.

Because new evidence shows survival rates DOUBLING, near total cancer cell elimination, and better quality of life.

But you can’t trust your doctor to bring it up…you’ll have to ask for it yourself.

So who was the man they tried to discredit?

Linus Pauling. And he wasn’t just any scientist.

He’s widely considered one of the greatest chemists in history and one of the only people ever to win two unshared Nobel Prizes.

In other words, this wasn’t a fringe thinker chasing wild ideas.

But late in his life, Pauling became convinced of something that shocked the medical world: That high doses of vitamin C could play a powerful role in fighting cancer.

He even published data showing cancer patients lived significantly longer when using it.

And for that? He was attacked, dismissed, and effectively erased from serious medical conversation.

Now, today’s researchers are revisiting Pauling’s work, using modern tools he never had. And what they’re finding lines up with his original insight.

Scientists are studying high-dose intravenous (IV) vitamin C in cancer patients with concentrated doses delivered directly into the bloodstream.

At those levels, vitamin C behaves very differently. Instead of acting like a standard antioxidant, it flips into a pro-oxidant. This creates a targeted burst of damage that cancer cells struggle to survive, while healthy cells, with better defenses, are largely spared.

And in lab studies, that effect isn’t subtle. High-dose vitamin C has been shown to wipe out up to 70–90% of certain cancer cells, including some of the most aggressive types like pancreatic and colorectal tumors.

And this isn’t just happening in labs. Clinics have been using IV vitamin C protocols for years, reporting consistent patient improvements.

In pancreatic cancer, one of the most lethal forms, patients receiving high-dose IV vitamin C alongside chemotherapy saw median survival nearly DOUBLE.

Patients have also reported 30–40% less fatigue, significantly reduced nausea, and an overall better quality of life during treatment. In some cases, they were able to tolerate more rounds of chemotherapy, something that can directly impact outcomes.

Which raises an uncomfortable question: If they were wrong about this for 40 years…

What are they dismissing RIGHT NOW that won’t be “rediscovered” until decades from now, long after today’s patients are gone?

The answer may have less to do with science and more to do with money.

Because there’s no patent on vitamin C. No billion-dollar drug pipeline behind it. Just a simple compound behaving in a very un-simple way.

If you or someone you love is facing cancer, it may be worth asking: “Is high-dose IV vitamin C something I should explore alongside standard care?”

Many integrative oncology clinics now offer it. And interest is growing fast.

To Linus,

Ray Thatcher
Research Director, Health Sciences Institute

Sources:

• Medscape. (2026). Vitamin C’s potential use in cancer getting second look. Retrieved from https://www.medscape.com/viewarticle/vitamin-cs-potential-use-cancer-getting-second-look-2026a1000ca3
• Welsh, J. L., Wagner, B. A., van’t Erve, T. J., Zehr, P. S., Berg, D. J., Halfdanarson, T. R., … Cullen, J. J. (2013). Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 71(3), 765–775. https://doi.org/10.1007/s00280-013-2070-8
• Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014). High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Science Translational Medicine, 6(222), 222ra18. https://doi.org/10.1126/scitranslmed.3007154
• Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., … Cullen, J. J. (2017). O2•− and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell, 31(4), 487–500.e8. https://doi.org/10.1016/j.ccell.2017.02.018
• Chen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., … Levine, M. (2005). Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proceedings of the National Academy of Sciences, 102(38), 13604–13609. https://doi.org/10.1073/pnas.0506390102
• Riordan, N. H., Riordan, H. D., Casciari, J. J., & Jackson, J. A. (2000). Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical Hypotheses, 54(3), 375–381. https://doi.org/10.1054/mehy.1999.0901